## Contents

**Program Faculty** ................................................................. 1
**Sponsorship and CME Credit** .................................................. ii
**CME Activity Assessment and Evaluation** ................................. iv

### Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

### Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
- Roman Perez-Soler ...................................................................... 4589s

### HKI-272 in Non–Small Cell Lung Cancer
- Kwok-Kin Wong ........................................................................ 4593s

### Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
- Mark A. Socinski ......................................................................... 4597s

### Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
- Daniel Morgensztern and Ramaswamy Govindan ......................... 4602s

### Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
- Philip D. Bonomi, Lela Buckingham, and John Coon ....................... 4606s

### Bevacizumab in Non–Small Cell Lung Cancer
- Alan Sandler ............................................................................... 4613s

### Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
- Emer O. Hanrahan and John V. Heymach ....................................... 4617s

### Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
- Gregory J. Riely and Vincent A. Miller ........................................ 4623s

### Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
- Bruce E. Johnson, David Jackman, and Pasi A. Jänne ..................... 4628s

### Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
- Julie E. Bauman, Keith D. Eaton, and Renato G. Martins ................. 4632s

### The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
- Jeffrey A. Engelman ..................................................................... 4637s

### Enzastaurin, a Protein Kinase Cδ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
- Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn ................ 4641s

### Incorporating Bortezomib into the Treatment of Lung Cancer
- Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara .......................................................... 4647s

### L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
- Randeep Sangha and Charles Butts ............................................... 4652s
Clinical Cancer Research

13 (15)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/15

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.